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Abstract
Background: Changes in DNA methylation of crucial cancer genes including tumor suppressors can occur early in
carcinogenesis, being potentially important early indicators of cancer. The objective of this study was to examine a
multiplexed approach to assess the methylation of tumor suppressor genes as tumor stratification and clinical
outcome prognostic biomarkers for lung cancer.
Methods: A multicandidate probe panel interrogated DNA for aberrant methylation status in 18 tumor suppressor
genes in lung cancer using a methylation-specific multiplex ligation-dependent probe amplification assay (MS-
MLPA). Lung cancer cell lines (n = 7), and primary lung tumors (n = 54) were examined using MS-MLPA.
Results: Genes frequently methylated in lung cancer cell lines including SCGB3A1, ID4, CCND2 were found among
the most commonly methylated in the lung tumors analyzed. HLTF, BNIP3, H2AFX, CACNA1G, TGIF, ID4 and
CACNA1A were identified as novel tumor suppressor candidates methylated in lung tumors. The most frequently
methylated genes in lung tumors were SCGB3A1 and DLC1 (both 50.0%). Methylation rates for ID4, DCL1, BNIP3,
H2AFX, CACNA1G and TIMP3 were significantly different between squamous and adenocarcinomas. Methylation of
RUNX3, SCGB3A1, SFRP4, and DLC1 was significantly associated with the extent of the disease when comparing
localized versus metastatic tumors. Moreover, methylation of HTLF, SFRP5 and TIMP3 were significantly associated
with overall survival.
Conclusions: MS-MLPA can be used for classification of certain types of lung tumors and clinical outcome
prediction. This latter is clinically relevant by offering an adjunct strategy for the clinical management of lung
cancer patients.
Background
Lung cancer is the third most frequent tumor, repre-
senting the leading cause of cancer death [1]. Non-small
cell lung cancer (NSCLC) is the most common variant.
NSCLC is the superseding term for various types of
lung cancer such as the most common ones, adenocarci-
nomas and squamous carcinomas [2-4]. Even within
patients at the earliest stages of the disease, a significant
number recur after therapeutic surgery and adjuvant
chemotherapy, and ultimately die from their disease.
Lung cancer cure rate remains disappointing, with five-
year survival rates limited to 15-20% [1]. Understanding
the molecular basis of lung cancer will enable the identi-
fication of high-risk populations for effective early detec-
tion, and prognostic and predictive markers of tumor
behaviour.
Lung cancer can be described as a molecular disease,
driven by the multistep accumulation of genetic, epige-
netic and environmental factors, among others [5,6].
Epigenetic alterations, including DNA methylation, his-
tone modifications, and miRNAs may result in silencing
of cancer-related genes. Alterations of DNA methylation
patterns have been recognized as the most common epi-
genetic events in human cancers. Aberrant methylation
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as CpG islands, located in or near the promoter region
of many genes, has been associated with the initiation
and progression of several types of cancer [7-11]. In
NSCLC, transcriptional inactivation of important tumor
suppressor, DNA repair, and metastasis inhibitor genes,
among others, has been reported [2,12]. Therefore, the
detection of aberrant promoter methylation of cancer-
related genes may be essential for the diagnosis, prog-
nosis and/or detection of metastatic potential of tumors,
including lung cancer. As the number of genes methy-
lated in cancer is large and increasing, sensitive and
robust multiplexed methods for detecting of aberrant
methylation of promoter regions are therefore, desirable.
Historically, the molecular pathogenesis of cancer has
been analyzed one gene at a time. CpG arrays represent
a high-throughput technology accelerating the discovery
of genes frequently hypermethylated during disease pro-
gression, also for lung cancer [13,14]. Methylation speci-
fic multiplex ligation-dependent probe amplification
(MS-MLPA) is a PCR-based technique allowing the
semiquantitative detection of changes in DNA promoter
methylation of multiple genes in a single experiment
[15,16]. Discrimination between methylated and
unmethylated targets is based on the annealing of
probes containing a recognition site for the methylation-
sensitive restriction enzyme HhaI. MS-MLPA has been
applied to the multiplexed measurement of methylated
genes in several diseases, including cancer [17-28]. Its
potential utility in lung cancer has not been character-
ized. In this study, we initially assessed, by MS-MLPA,
whether a selected panel of candidate tumour suppres-
sor genes could be methylated in lung cell lines and
tumors. Next, we determined whether the methylation
status of such genes could contribute for lung tumor
stratification and clinical outcome prognosis.
Methods
Lung cancer cell lines
Six NSCLC cell lines consisting of three adenocarci-
noma cell lines (A549, H522 and H358), two large carci-
noma cell lines (H460, H661), and one squamous cell
carcinoma cell line (H226), as well as one small cell
lung cancer cell line (SCLC) (H841) were obtained from
the American Type Culture Collection (Rockville, MD,
US), grown in RPMI-1640 medium (Sigma) supplemen-
ted with 10% fetal bovine serum, and collected under
standard tissue culture protocols. The lung cancer cell
line, H460, was included in all sample runs in order to
test the reproducibility of the MS-MLPA test.
Tumor samples
The study cohort consisted of a series of archived paraf-
fin-embedded blocks from 54 NSCLC patients. Patients
with local disease (stage I to resectable stage III) were
treated surgically and those with advanced disease (stage
III and IV) received systemic and/or local treatment.
Primary lung tumors were collected after institutional
review board approval and handled anonymously follow-
ing ethical and legal protection guidelines of human
subjects. The observation period ranged from 2 to
79 months, with a median follow-up of 20,5 months.
Inclusion criteria of newly diagnosed lung cancer
patients were based on the histopathologic information,
covering from early to advanced stages. It was also
required to have tissue material available for obtaining
high-quality DNA for methylation analyses. Of the 54
NSCLC patients, 22 had TNM Stage I-II, 18 had Stage
III, and 14 stage IV defined under standard criteria [29].
The tumors were histologically classified as adenocarci-
nomas (n = 32), squamous cell carcinomas (n = 21) and
large cell carcinoma (n = 1) according to the histological
typing of lung tumors of the World Health Organization
[29]. Demographic and clinicopathologic information of
the lung cases analyzed is described in Table 1.
Table 1 Demographic and clinicopathologic information
of the lung cases analyzed
Clinical Parameters Cases n (%)
Age ≥65 28 (51.9%)
<65 26 (48.1%)
Gender Male 37 (68.5%)
Female 17 (31.5%)
Smoking history Yes 46 (85%)
No 6 (11%)
Unknown 2 (3%)
Karnosfsky ≥80 45 (83.3%)
<80 9 (16.7%)
Histology Squamous Cell Carcinoma 21 (38.5%)
Adenocarcinoma 32 (59.6%)
Large Cell Carcinoma 1 (1.9%)
Differentation grade Good differentiated 11 (20.4%)
Moderate 16 (29.6%)
Poor 27 (50%)
Stage I-II 22 (40.7%)
III 18 (33.3%)
IV 14 (26%)
Local/Advanced Local (stage I II) 22 (40.7%)
Advanced (stage III-IV) 32 (59.3%)
Progression Yes 26 (48.1%)
No 28 (51.9%)
Death Yes 25 (46.3%)
No 29 (53.7%)
Summary of the distribution of the following variables among patients
studied: age, gender, smoking history, Karnofsky status, histology,
differentiation grade, stage, extension of disease, and the number of cases
progressing or dying of the disease during the study.
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Genomic DNA from cell lines and tissue was extracted
using standard methods. Paraffin-embedded tissues
were macro-dissected based on hematoxylin-eosin eva-
luations to ensure a minimum of 75% of tumor cells
[30]. Corresponding slides were digested using protei-
nase K (Roche Diagnostics GmbH, Mannheim,
Germany) overnight before DNA extraction. Concentra-
tion and purity of DNA samples were determined with
a ND-1000 spectrophotometer (NanoDrop Technolo-
gies, Wilmington, DE, USA). DNA quality was evalu-
ated based on 260/280 ratios of absorbances and the
integrity was also checked by gel electrophoresis analy-
sis using the Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Palo Alto CA).
Methylation-Specific Multiplex Ligation-Dependent Probe
Amplification (MS-MLPA)
The present study used the MS-MLPA probe set ME003
(MRC-Holland, Amsterdam, The Netherlands) which
can simultaneously check for aberrant methylation at
one or two CpG dinucleotides of the following proven
or suspected 18 tumor suppressor genes (Table 2).
Probe sequences, gene loci and chromosome locations
can be found at http://www.mlpa.com (date of acces-
sion: 25-May-2010). Several genes were evaluated by
two probes, which recognized different Hha1 restriction
sites in their promoter regions. The experimental proce-
dure was carried out and results analyzed according to
the manufacturer’s instructions, with minor modifica-
tions. In short, DNA (200 ng) was dissolved up to 5 μl
Table 2 Information of the tumor suppressor genes analyzed
Gene Name
a Probes Functional implications Chromosomal
Localization
b
PRDM2 PR domain containing 2, with ZNF domain 09146-L02862 Cell cycle control 1p36
RUNX3 Runt-related transcription factor 3 11131-L03905 TGFB signaling 1p36
RARB Retinoic acid receptor beta 10362-L10900 Cell differentiation and
proliferation
3p24
HLTF Helicase-like transcription factor 09152-L09384(probe 1) 02758-
L02207(probe 2)
Transcription regulation 3q25.1-q26.1
SCGB3A1 Secretoglobin, family 3A, member 1 03305-L09382 (probe1) 11132-
L12956(probe 2)
Cell differentiation and
proliferation
5q35-qter
ID4 Inhibitor of DNA binding 4, dominant negative
helix-loop-helix protein
04497-L03909(probe 1) 04496-
L03908(probe 2)
Transcription regulation 6p22.3
TWIST1 Twist homolog 1 (Drosophila) 02080-L02886 Cell differentiation and
proliferation
7p21
SFRP4 Secreted frizzled-related protein 4 03744-L03204(probe 1) 09147-
L03205(probe 2)
WNT antagonism 7p14.1
DLC1 Deleted in liver cancer 1 02754-L02203(probe 1) 02753-
L02202(probe 2)
Cell differentiation and
proliferation
8p22
SFRP5 Secreted frizzled-related protein 5 09149-L03207(probe 1) 09148-
L12957(probe 2)
WNT antagonism 10q24
BNIP3 BCL2/adenovirus E1B 19kDa Interacting protein 3 07138-L12958 Proliferation and
apoptosis
10q.26.3
H2AFX H2A histone family, member X 08511-L08607(probe 1) 08509-
L08605(probe 2)
Transcription regulation 11q23.3
CCND2 Cyclin D2 03313-L02668(probe 1) 03312-
L09381(probe 2)
Cell cycle control 12p13
CACNA1G Calcium channel, voltage-dependent, T type, alpha
1G subunit
10123-L10466 Cell differentiation and
proliferation
17q22
TGIF TGFB-induced factor homebox 1 02850-L13256 TGFB signaling 18p11.31
BCL2 B-cell CLL/lymphoma2 10352-L10890 Proliferation and
apoptosis
18q21.3
CACNA1A Calcium channel, voltage-dependent, P/Q type,
alpha 1A subunit
09055-L09224 Cell differentiation and
proliferation
19p13
TIMP3 TIMP metallopeptidase inhibitor 3 10357-L10895(probe 1) 10354-
L10892(probe 2)
Invasion and metastasis 22q12.3
Summary of the gene description, probes, functional implications, and chromosomal location of the tumor suppressor genes analyzed in this study.
Gene names in bold highlight novel candidates never reported to be methylated in lung cancer to date. a. Human Genome Organization Nomenclature;
b. Approved gene name from Human Genome Organization available at http://www.genenames.org/
Castro et al. Journal of Translational Medicine 2010, 8:86
http://www.translational-medicine.com/content/8/1/86
Page 3 of 11TE-buffer (10 mM Tris pH 8.2, 1 mM EDTA pH 8.0),
denatured and subsequently cooled down to 25°C. After
adding the probe mix, the probes were allowed to hybri-
dize (16 h at 60°C). Subsequently, the samples were
divided in two: one half of the samples were ligated,
whereas for the other part of the samples, ligation was
combined with the HhaI digestion enzyme. This diges-
tion resulted in ligation of only the methylated
sequences. PCR was performed on both parts of the
samples in a volume of 50 μl containing 10 μlo ft h e
ligation reaction mixture using a thermal cycler (MJ
Research Inc., Waltham, MA, USA), with 35 cycles of
denaturation at 95°C for 30 s, annealing at 60°C for 30 s
and extension at 72°C for 1 min with a final extension
of 20 min at 72°C. Aliquots of 2 μl of the PCR reaction
were combined with 0.12 μl LIZ-labeled internal size
standard (Applied Biosystems, Foster City, CA, USA)
and 9.0 μl deionized formamide. After denaturation,
fragments were separated and quantified by electrophor-
esis on an ABI 3700 capillary sequencer and the Peak
Scanner v1.0 analysis software (both Applied Biosys-
tems). Peak identification and values corresponding to
peak size in base pairs (bp), and peak areas were used
for further data processing. Automated fragment and
data analysis was performed exporting the peak areas to
an excel-based analysis program (Coffalyser V8, MRC-
Holland). For hypermethylation analysis the ‘relative
peak value’ or the so-called ‘probe fraction’ of the liga-
tion-digestion sample is divided by the ‘relative peak
value’ of the corresponding ligation (undigested) sample,
resulting in a so-called ‘methylation-ratio’ (M-ratio).
Aberrant methylation was scored when the calculated
M-ratio was ≥0.30, corresponding to 30% of methylated
DNA. The methylated ratios were interpreted as absence
of hypermethylation (0.00-0.29), mild hypermethylation
(0.30-0.49), moderate hypermethylation (0.50-0.69), and
extensive hypermethylation (>0.70). In genes with more
than one probe, their ratios were calculated indepen-
dently for methylation analysis.
Statistical Analysis
Coefficients of variation for each probe were estimated
based on the ratio of the standard deviation and the
respective mean of four replicates of the H460 cell line.
Associations among MS-MLPA methylation and tumor
s t a g ea n dg r a d ew e r ee v a l u a t ed using non-parametric
Wilcoxon-Mann-Whitney and Kruskall-Wallis tests
using Bonferroni adjustment for multiple testing. Asso-
ciations between methylation candidates were analyzed
using Kendall’s tau ß test, considering only two-sided
p-values 0.05 to be statistically significant. For each
probe of the assay, methylation was scored when the
calculated M-ratio was ≥0.30. Associations of methyla-
tion of each gene probe with overall survival were also
evaluated using the log-rank test in those cases for
which follow-up information were available. Overall sur-
vival time was defined as the months elapsed between
surgery and death as a result of disease (or the last fol-
low-up date). Patients who were alive at the last follow-
up or lost to follow-up were censored. Survival curves
were plotted using the standard Kaplan-Meier metho-
dology [31]. Statistical analyses were performed using
the SPSS statistical package (SPSS 17.0.1 for Windows
2009, Chicago, IL, USA).
Results
Quality assessment of MS-MLPA assay
In order to test the reproducibility of the assay, a lung
cancer cell line, H460, was included as control samples
each assay run. The methylation ratios of these repli-
cated experiments of the cell line analyzed and their
coefficients of variation are shown in additional file 1,
Table S1. Using the thresholds defined above for methy-
lation detection suggested high reproducibility of the
methylation profiles. In conclusion, these initial analyses
revealed reproducible results allowing methylation
assessment using the selected panel of candidate genes.
MS-MLPA profiles of lung cancer cell lines
The methylation profiles of the 18 genes under study
were initially tested in seven cell lines derived from lung
tumors of different histopathologic variants. Additional
file 2, Table S2 provides an overview of the methylation
patterns of these cell lines grouped based on the histo-
pathology of the tumors from which these lung cancer
cell lines were derived from. The percentual methylation
for each gene is provided as well. Several genes:
SCGB3A1, ID4, SFRP5, CCND2, and CACNA1A, were
found methylated in at least 4 out of the 7 cell lines
analyzed, covering various histopathologic types. These
initial analyses suggested that the panel of candidate
genes selected could be appropriate to detect aberrant
methylation profiles in human lung tumors.
MS-MLPA profiles for clinico-histopathologic stratification
of lung tumors
In the next step, we tested whether MS-MLPA could be
applied to lung tumors (Figure 1, Table 3). Overall, the
most frequent hypermethylated genes found by MS-
MLPA were DLC1 (50%), SCGB3A1 (50.0%), CCND2
(48.1%), ID4 (46.3%), BNIP3 (44.4%), RUNX3 (42.5%),
and PRDM2 (40.7%). Notably, genes methylated in lung
tumor specimens frequently overlapped with those
found to be methylated in the lung cancer cell lines as
shown above. Promoter hypermethylation of genes pre-
viously reported methylated in lung cancer included
PRDM2, RUNX3, RARB, SCGB3A1, TWIST1, SFRP4,
DLC1, SFRP5, CCND2, BCL2 and TIMP3 (Reviewed in
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tified for HLTF, ID4, BNIP3, H2AFX, CACNA1G, CAC-
NA1A, and TGIF. The percentual methylation rates of
each gene depending on the different clinicopathologic
variables are shown in Table 3. The genes more fre-
quently methylated in adenocarcinomas were: RARB,
TWIST1, and CACNA1A, while the most commonly
methylated genes in squamous tumors were SCGB3A1,
ID4, SFRP4, SFRP5, DCL1, BNIP3, H2AFX, CACNA1G,
TGIF, TIMP3 and BCL2. Statistically significantly differ-
ent methylation rates were observed for ID4-2 (p =
0.011), DCL1 (p = 0.019), BNIP3 (p = 0.003), H2AFX (p
= 0.001), H2AFX-2 (p = 0.005), CACNA1G (p = 0.007)
and TIMP3 (p = 0.021) when comparing squamous ver-
sus adenocarcinoma cases. When comparing methyla-
tion rates in localized tumors versus metastatic disease,
the methylation of RUNX3 (p = 0.013), SCGB3A1-2 (p
= 0.008), SFRP4-2 (p = 0.022), and DLC1 (p = 0.016)
was significantly associated with the presence of meta-
static disease. The methylation of the same genes was
also associated with tumor stage RUNX3 (p = 0.040),
SCGB3A1 (p = 0.032), SFRP4 (p = 0.033), and DLC1
(p = 0.035). RARB methylation (p = 0.028) was asso-
ciated with the Karnofsky status. Methylation of several
genes was simultaneously present in the lung tumors
analyzed, as revealed by Kendall’s tau correlations
shown in additional file 4, Table S4. We did not find
any significant association between methylation of the
genes under study and age, gender, smoking history
(data not shown). Methylation rates regarding histology
lung subtypes, differentiation grade and tumor stage
(comparing localized versus advanced disease), are pro-
vided in Table 3. In conclusion, this set of analyses sug-
gested that the panel of candidate genes selected could
be of clinical relevance for the clinicopathologic staging
of human lung tumors.
MS-MLPA profiles for clinical outcome prognosis for lung
cancer patients
In the next step, we tested whether MS-MLPA could be
applied to differentiate patients with different clinical
outcome, using overall survival as the clinical endpoint.
We observed that patients with tumors methylated for
the HTLF gene showed an overall survival significantly
shorter as compared to patients unmethylated for HTLF
(log rank, p = 0.035; Figure 2A). In contrast, survival
was significantly longer in patients with methylation for
S F R P 5( p r o b e2 )( l o gr a n k ,p=0 . 0 2 1 ;F i g u r e2 B ) ;a n d
Figure 1 Methylation profiles of lung tumors. The methylated ratios were interpreted as absence of hypermethylation (0.00-0.29), highlighted
as white cells; mild hypermethylation (0.30-0.49) highlighted as light grey cells; moderate hypermethylation (0.50-0.69), highlighted as medium
grey cells; and extensive hypermethylation (0.70-1.00), highlighted as dark grey cells. Gene names in bold highlight novel candidates never
reported to be methylated in lung cancer to date. Advanced tumors are highlighted with dots. LC: large cell carcinomas.
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patients with no aberrant methylation of these genes.
Importantly, this set of analyses indicated that the
methylation of three genes was significantly associated
with overall survival, suggesting that the panel of candi-
date genes under analyses could be of clinical relevance
as prognosticators of the clinical outcome of patients
affected with lung tumors.
Discussion
The present study evaluates the application of a multi-
plexed methylation technique in lung cancer. MS-MLPA
was initially tested in cell lines and tissue specimens
representing different steps of lung cancer progression
supporting the panel of the tumor suppressor genes
selected to be altered in lung cancer. In this study, we
included genes with important roles in cell cycle control
(PRDM2, CCND2), transcription regulation (HTLF, ID4,
H2AFX), TGF-b signaling (RUNX3, TGIF), WNT antag-
onism (SFRP4, SFRP5), cell differentiation and prolifera-
tion (SCGB3A1, TWIST1, RARB, CACNA1A,
CACNA1G, DLC1), proliferation and apoptosis (BNIP3,
BCL2), and invasion and metastasis (TIMP3). Our pre-
sent data is in concordance with previous reports show-
ing altered methylation patterns in lung cancer in genes
such as PRDM2 [32], RUNX3 [33-38], RARB [37,39-41],
SCGB3A1 [42,43], TWIST1 [44], DLC1 [45,46], SFRP4
[36,44], SFRP5 [36,38,44,47], CCND2 [40,41,48,49],
BCL2 [50] and TIMP3 [14,46,51]. Importantly, our
study identified seven novel methylated candidates in
Table 3 Summary of the frequency of methylation of the genes in lung tumors based of their main clinicopathologic
variables
Gene Overall (%) Histology (%) Differentation Grade (%) Tumor stage (%)
Methylation n = 54 SCC n = 21 ADC n = 32 Good n = 11 Moderate n = 16 Poor n = 27 Local n = 22 Advanced n = 32
PRDM2 22 (40.7) 10 (45.4) 12 (37.5) 21 (45.6) 0 (0) 12 (44.4) 10 (45.4) 12 (37.5)
RUNX3 23 (42.5) 13 (59.1) 10 (31.2) 19 (41.3) 2 (33.3) 10 (37.0) 13 (59.1) 10 (31.2)
RARB 20 (37) 8 (36.4) 12 (37.5) 17 (36.9) 3 (50.0) 10 (37.0) 8 (36.4) 12 (37.5)
HLTF 8 (14.8) 1 (4.5) 7 (21.9) 8 (17.4) 0 (0) 7 (25.9) 1 (4.5) 7 (21.9)
HLT-2 17 (31.5) 9 (40.9) 8 (25.0) 14 (30.4) 2 (33.3) 10 (37.0) 9 (40.9) 8 (25.0)
SCGB3A1 27 (50.0) 15 (68.2) 12 (37.5) 24 (52.2) 2 (33.3) 15 (55.5) 15 (68.2) 12 (37.5)
SCGB3A1-2 17 (31.5) 12 (54.5) 5 (15.6) 12 (26.0) 4 (66.7) 9 (33.3) 12 (54.5) 5 (15.6)
ID4 25 (46.3) 12 (54.5) 13 (40.6) 23 (50.0) 1 (1.7) 12 (44.4) 12 (54.5) 13 (40.6)
ID4-2 11 (20.4) 5 (22.7) 6 (18.7) 10 (21.7) 1 (1.7) 7 (25.9) 5 (22.7) 6 (18.7)
TWIST1 21 (38.9) 9 (40.9) 12 (37.5) 19 (41.3) 2 (33.3) 10 (37.0) 9 (40.9) 12 (37.5)
SFRP4 10 (18.5) 7 (31.8) 3 (9.4) 9 (19.5) 1 (1.7) 5 (18.5) 7 (31.8) 3 (9.4)
SFRP4-2 16 (29.6) 11 (50.0) 5 (15.6) 12 (26.0) 3 (50.0) 8 (29.6) 11 (50.0) 5 (15.6)
DLC1 22 (40.7) 12 (54.5) 10 (31.2) 18 (39.1) 3 (50.0) 13 (48.1) 12 (54.5) 10 (31.2)
DLC1-2 27 (50.0) 15 (68.2) 12 (37.5) 21 (45.6) 5 (83.3) 14 (51.8) 15 (68.2) 12 (37.5)
SFRP5 17 (31.5) 8 (36.4) 9 (28.1) 15 (32.6) 2 (33.3) 10 (37.0) 8 (36.4) 9 (28.1)
SFRP5-2 12 (22.2) 6 (27.3) 6 (18.7) 9 (19.6) 2 (33.3) 8 (29.6) 6 (27.3) 6 (18.7)
BNIP3 24 (44.4) 12 (54.5) 12 (37.5) 20 (43.5) 2 (33.3) 13 (48.1) 12 (54.5) 12 (37.5)
H2AFX 10 (18.5) 5 (22.7) 5 (15.6) 9 (19.5) 1 (1.7) 6 (22.2) 5 (22.7) 5 (15.6)
H2AFX-2 9 (16.7) 6 (27.3) 3 (9.4) 8 (17.4) 1 (1.7) 5 (18.5) 6 (27.3) 3 (9.4)
CCND2 26 (48.1) 13 (59.1) 13 (40.6) 22 (47.8) 3 (50.0) 15 (55.5) 13 (59.1) 13 (40.6)
CCND2-2 29 (53.7) 14 (63.6) 15 (46.9) 25 (54.3) 4 (66.7) 15 (55.5) 14 (63.6) 15 (46.9)
CACNA1G 21 (38.9) 12 (54.5) 9 (28.1) 19 (41.3) 1 (1.7) 12 (44.4) 12 (54.5) 9 (28.1)
TGIF 10 (18.5) 5 (22.7) 5 (15.6) 9 (19.5) 1 (1.7) 6 (22.2) 5 (22.7) 5 (15.6)
BCL2 8 (14.8) 4 (18.2) 4 (12.5) 8 (17.4) 0 (0) 5 (18.5) 4 (18.2) 4 (12.5)
CACNA1A 18 (33.3) 11 (50.0) 7 (21.9) 13 (28.3) 4 (66.7) 8 (29.6) 11 (50.0) 7 (21.9)
TIMP3 10 (18.5) 7 (31.8) 3 (9.4) 9 (19.6) 1 (1.7) 5 (18.5) 7 (31.8) 3 (9.4)
TIMP3-2 11 (20.4) 7 (31.8) 4 (12.5) 9 (19.6) 1 (1.7) 6 (22.2) 7 (31.8) 4 (12.5)
The number of samples (n) displaying a methylation ratio higher than 0.3, as well as their percentual frequency within each group of specimens under analyses
was included.
Highlighted genes in bold represented novel candidates never reported methylated in lung cancer to date. Ys: years; SCC: squamous cell carcinoma; ADC:
adenocarcinoma.
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CACNA1G, CACNA1A and TGIF. The clinical outcome
of the patients whose tumors were analyzed using this
technique revealed that individual tumors behaved
according to histopathologic staging and also to their
methylation patterns analyzed using this type of multi-
plexed strategy. The MS-MLPA approach thereby
offered an opportunity to test and improve histopatholo-
gic stratification and also prognostic statements. This
latter is clinically relevant since it offers an alternative
adjunct strategy for the clinical management of patients
affected with lung cancer.
Among the high-throughput techniques available
today for epigenetic alterations assessment, the CpG
array represents the main comprehensive platform
already applied to identify methylation candidates in
lung cancer [13,14]. To our knowledge, the multiplexed
MS-MLPA technique has not been employed to analyze
the methylation profiles in lung cancer. The advantages
of MS-MLPA technique as an alternative for MS-PCR
include: allowing screening of multiple predefined pro-
moter methylation candidates in one experiment using a
low amount of DNA (100-200 ng), being feasible using
DNA extracted from tissue (even in formalin fixed
material), providing semiquantitative data, and requiring
only standard laboratory equipment. Furthermore, the
(potentially) troublesome bisulfite conversion of
unmethylated cytosines required for MS-PCR can be
omitted in MS-MLPA using a methylation-sensitive
digestion. Methylation indices for the majority of the
probes under study were consistent and reproducible.
Overall, the variation of the methylation ratios obtained
for each probe revealed inter-assay reproducibility reli-
able enough for clinical practice.
Figure 2 Methylation profiles as clinical outcome prognosticators for lung cancer patients. A) Kaplan-Mayer curve survival analysis
indicating that tumors methylated for HTLF showed poor survival than those unmethylated for this gene (log rank, p = 0.035). B) Kaplan-Mayer
curve survival analysis indicating that tumors methylated for SFRP5-2 (probe 2) showed better survival than those unmethylated for this gene
(log rank, p = 0.021). C) Kaplan-Mayer curve survival analysis indicating that tumors methylated for TIMP3 showed better survival than those
unmethylated for this gene (log rank, p = 0.030).
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in lung cancer cell lines provided first insights of the
potential impact of these candidate genes for human
lung cancer. Results of the tumor set for the top differ-
entiating genes concurred with the main MS-MLPA
results in the cells set (supporting the cancer specificity
of the methylated candidates), and also with previous
reports describing methylation for some of the candi-
dates under study, such as PRDM2 [32], RUNX3
[35,36], SFRP4 and SFRP5 [36], SCGB3A1 [43], DLC1
[46], CCND2 [48]. In our series, RUNX3 [33-35,38],
SCGB3A1 [43], CCND2 [49] exhibited higher methyla-
tion rates as compared to these reports; whereas SFRP4
a n dS F R P 5[ 4 4 ] ,D L C 1[ 4 5 ] ,T I M P 3[ 5 1 ]s h o w e dl o w e r
methylation rates than previous studies. In addition to
the inter-individual variation, these differences could be
attributed to several issues: 1) it is important to be
aware that aberrant methylation needs to meet the cut-
off ratio of 30% or greater set by the mathematical algo-
rithm designed to distinguish legitimate methylation
peaks. Variation in cutoff setting would render improved
accuracies for each specific gene. 2) Discrepancy in the
frequency of methylation mig h tb ea t t r i b u t e di np a r tt o
the number and type of stages analyzed. 3) Heterogene-
ity of the promoter methylation may exist within the
individual gene promoters for certain genes in lung can-
cer carcinomas. MS-MLPA is only based on a single
CpG site compared to an average of 4-6 CpG sites in
MS-PCR assays. Since only a small part of the promotor
is usually analyzed by MS-MLPA, the methylation of
additional of nearby CpG islands cannot be excluded. 4)
Availability of two probes targeting different CpG
islands with different methylation ratios for two of the
genes analyzed served to highlight the differential
methylation and potential consequences of each specific
CpG site within a gene. The relative impact of each site
was observed for those genes for which different probes
were included targeting different CpG sites displaying
different methylation rates. 5) MS-MLPA ratios may
potentially be underestimated due to the presence of
normal (U) ‘contaminating’ cells in the tumor sample.
However, whereas the detection of an unmethylated
promoter next to methylated sequences is usually disre-
garded as originating from normal tissue, it may fre-
quently reflect tumor heterogeneity and the
polyclonality of the tumors regarding hypermethylation.
Despite of not containing a lung cancer specific panel
of tumor suppressors, we observed correlation of hyper-
methylation with lung cancer histopathologic variables.
We detected distinct methylation profiles between squa-
mous and adenocarcinomas, in concordance with pre-
vious reports evaluating part of the genes analyzed using
MS-PCR methods [33-37,41-45,48,51]. Among the novel
methylated candidates identified, ID4, BNIP3, H2AFX,
CACNA 1G, TGIF were more frequently methylated in
squamous tumors, while HTLF and CACNA1A were
commonly methylated in adenocarcinomas. In agree-
ment with previous observations, methylation of
RUNX3 [36,38], SCGB3A1 [42], DLC1 [45] and SFRP4
[36,44], was identified as early events associated with
early differentiation and stage. The presence of different
methylation patterns in different tumor stages supports
the notion that epigenetic events may be involved in
tumor progression, after the accumulation of additional
genomic instability, and other epigenetic and genetic
events [5,36]. Kendall’s tau associations revealed the fre-
quent simultaneous methylation of the genes analyzed,
especially for TIMP3 and H2AFX, SFRP5 and HTLF,
and CACNA1G and BNIP3. These observations high-
light how epigenetic regulation impact on different can-
cer genes carrying out critical cell functions in
neoplastic cells. Importantly, the methylation of three of
the genes analyzed (HTLF, SFRP5 and TIMP3) was
associated with clinical outcome. Hypermethylation of
HTLF was associated with poor survival, in agreement
with previous studies indicating the silencing of the
gene by methylation predicting colorectal cancer recur-
rence [52]. On the other hand, hypermethylation of
SFRP5 and TIMP3 was associated with improved survi-
val. TIMP3 methylation was also previously found asso-
ciated with better survival in NSCLC [51], and bladder
cancer [53]. These findings are clinically relevant for the
adjunct potential of the methylation assessment of any
of these three to identify lung cancer patients more
likely to show a poor clinical behavior. Since the biology
and the mechanisms by which these genes play a tumor
suppressor role is not fully characterized, and due to the
limited number of cases analyzed, the interpretation of
the prognostic significance of their promoter hyper-
methylation may warrant further investigation.
Conclusions
MS-MLPA allowed identification of a number of new
and possibly interesting epigenetic alterations such as
H L T F ,I D 4 ,B N I P 3 ,H 2 A F X ,C A C N A 1 G ,C A C N A 1 A
and TGIF genes, serving to gain more insight into the
development of lung carcinomas. This report highlights
that the identification of aberrant methylation in promo-
ter regions of cancer genes yields important tumor bio-
markers, underscoring a role for epigenetics in the early
pathogenesis of the major histological subtypes of lung
cancer. The innovative applicability of MS-MLPA in the
types of samples analyzed contributed to the further
u n d e r s t a n d i n go fl u n gc a n c e r biology. To what extent
these genes contribute or are functionally involved in
the different steps during tumorigenesis and cancer pro-
gression remains to be determined. These genes would
represent attractive targets for cancer therapy, given the
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Page 8 of 11reversible nature of epigenetic gene silencing. Impor-
tantly, the clinical translational applications of the MS-
MLPA platform using tissue paraffin/embedded material
relate not only to adjunct tumor classification, but also
for clinical outcome prognosis. The general character of
the assay used (with predefined tumor suppressor genes
not necessary specific to any tumor type) suggested the
need to investigate regions that would be more relevant
for lung cancer and to develop targeted tumor-specific
customized MS-MLPA assays. Considering that the
mortality of lung cancer could be greatly reduced
through detection of the disease at the earliest stages, in
the near future, the semiquantitative aspect of MS-
MLPA may prove to play a role not only for clinical
outcome prognosis and risk stratification but may also
aid for early detection and follow-up of lung cancer
patients, and predict therapeutic response.
Additional material
Additional file 1: Table S1: Quality assessment of methylation
profiles: Inter-assay reproducibility including coefficient of variations
among replicates of each probe for the lung control cell line. The
methylated ratios were interpreted as absence of hypermethylation (0.00-
0.29), highlighted as white cells; mild hypermethylation (0.30-0.49)
highlighted as light grey cells; moderate hypermethylation (0.50-0.69),
highlighted as medium grey cells; and extensive hypermethylation (0.70-
1.00), highlighted as dark grey cells. Gene names in bold highlight novel
candidates never reported to be methylated in lung cancer to date.
Additional file 2: Table S2: Methylation profiles of lung cancer cell
lines. The methylated ratios were interpreted as absence of
hypermethylation (0.00-0.29), highlighted as white cells; mild
hypermethylation (0.30-0.49) highlighted as light grey cells; moderate
hypermethylation (0.50-0.69), highlighted as medium grey cells; and
extensive hypermethylation (0.70-1.00), highlighted as dark grey cells.
Gene names in bold highlight novel candidates never reported to be
methylated in lung cancer to date. Cell lines derived from metastatic
tumors are highlighted with dots. SCC: squamous cell carcinoma; LC:
large cell carcinoma; SCLC: small cell lung cancer
Additional file 3: Table S3: Complementary information of the
genes analyzed using MS-MLPA. Review of the functional implications
and methylation studies of the candidate genes analyzed in this study in
lung cancer.
Additional file 4: Table S4: Kendall’s tau correlation coefficients
evaluating associations among the candidate genes. Two sided
significant coefficients are highlighted in grey.
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